Bristol Myers Squibb has entered a multi year collaboration with Faro Health to enhance the design and execution of clinical trials using artificial intelligence. The agreement will see the company adopt Faro’s digital protocol platform as a central system for structuring and managing trial protocols across its global development programmes.

The partnership focuses on improving how clinical studies are planned, drafted and optimised, with the aim of increasing efficiency and consistency. By introducing structured data and AI enabled workflows, the companies intend to reduce complexity in protocol development and support faster decision making.

Faro’s technology is designed to standardise protocol design, creating a foundation that can scale AI use across multiple studies. This approach is expected to help streamline clinical operations while maintaining quality and regulatory compliance.

For Bristol Myers Squibb, the collaboration reflects a broader strategy to integrate advanced digital tools into drug development. The move highlights growing industry interest in AI to accelerate timelines, improve trial outcomes and ultimately bring new therapies to patients more efficiently.